TL;DR
Diabetic lower limb ischemia is a serious condition with limited treatment options. This study shows that exosomes derived from adipose-derived mesenchymal stem cells (ADSC-Exos) can significantly improve the repair of diabetic hindlimb ischemia in mice. This therapeutic effect is mediated by exosomal miR-125b-5p, which targets and suppresses alkaline ceramidase 2 (ACER2), thereby promoting muscle cell proliferation and migration.
What Problem Does This Paper Address?
Diabetic lower limb ischemia is a severe complication of diabetes, leading to impaired blood flow, poor wound healing, and potentially amputation. Current treatments are often insufficient, highlighting the need for novel therapeutic strategies. Mesenchymal stem cells (MSCs) show promise, but their direct clinical application faces challenges like poor survival and controlled differentiation. Exosomes, released by MSCs, offer a cell-free alternative with similar therapeutic potential, but their specific mechanisms in diabetic lower limb ischemia are not fully understood. This paper investigates the efficacy of ADSC-Exos in treating diabetic hindlimb ischemia and elucidates the underlying molecular mechanisms, focusing on the role of microRNAs.
Methods
The researchers employed a multi-faceted approach:
- Isolation and Characterization of ADSCs and ADSC-Exos: ADSCs were isolated from human adipose tissue and characterized using flow cytometry and differentiation assays. ADSC-Exos were isolated using differential ultracentrifugation and characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blotting for exosomal markers.
- In Vitro Assays:
- Cell Proliferation and Migration: C2C12 myoblasts were treated with ADSC-Exos, and their proliferation was assessed using EdU assays, while migration was evaluated using Transwell assays.
- Angiogenesis: Human umbilical vein endothelial cells (HUVECs) were used to assess the pro-angiogenic potential of ADSC-Exos through in vitro tube formation assays.
- miRNA Analysis: miRNA sequencing (miRNA-seq) was performed on ADSC-Exos to identify abundant miRNAs.
- miRNA Mimic/Inhibitor Assays: C2C12 cells were transfected with miR-125b-5p mimics or inhibitors to study its direct effects on cell proliferation and migration.
- Target Validation: Bioinformatic tools (miRDB, TargetScan, starBase) were used to predict miR-125b-5p targets. The interaction between miR-125b-5p and ACER2 was validated using dual-luciferase reporter assays and by measuring mRNA and protein levels of ACER2.
- ACER2 Overexpression: C2C12 cells were transfected with an ACER2 expression plasmid to investigate the functional consequences of ACER2 overexpression on cell proliferation and migration.
- In Vivo Model: A diabetic hindlimb ischemia (HLI) model was established in mice by inducing diabetes with streptozotocin (STZ) followed by femoral artery and vein ligation. Treatments (ADSC-Exos, ADSCs, or PBS as control) were administered locally.
- Functional Recovery Assessment: Limb blood perfusion was measured using Laser-Doppler Perfusion Imaging (LDPI). Limb motor function and limb salvage were scored.
- Histological Analysis: Muscle tissues from the ischemic limbs were analyzed using Hematoxylin and Eosin (H&E) and Masson staining to assess inflammation, muscle fiber regeneration, and collagen deposition. Immunofluorescence staining for CD34 (endothelial cells) and α-SMA (smooth muscle cells) was performed to evaluate neovascularization.
- Bioinformatics Analysis: Microarray gene expression data from diabetic HLI models were analyzed to identify differentially expressed genes and pathways, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses.
Datasets
- Microarray Data: The study utilized publicly available microarray gene expression profiling data of hindlimb ischemia in diabetic mice (dataset GSE3313). This dataset contains data from both wild-type and diabetic (Lepr db/db) mice at four different time points.
Key Insights and Ideas
- ADSC-Exos as a potent therapeutic for diabetic HLI: The study provides strong evidence that ADSC-Exos can significantly accelerate the repair of diabetic hindlimb ischemia, improving blood flow, muscle regeneration, and vascularization.
- miR-125b-5p is a key mediator of ADSC-Exo efficacy: The research pinpoints miR-125b-5p as a crucial exosomal cargo responsible for the protective effects of ADSC-Exos. Its transfer into target cells enhances their function.
- ACER2 is a direct target of miR-125b-5p: The study successfully identifies alkaline ceramidase 2 (ACER2) as a direct downstream target of miR-125b-5p, demonstrating a specific molecular interaction that underlies the observed cellular effects.
- miR-125b-5p/ACER2 axis regulates cell function: The findings reveal that miR-125b-5p promotes C2C12 cell proliferation and migration by suppressing ACER2 expression, highlighting a novel regulatory axis in muscle repair.
- AMPK signaling pathway involvement: The study suggests a potential role for the AMPK signaling pathway in diabetic HLI and its modulation by miR-125b-5p, opening avenues for further investigation.
Key Results
- In Vitro: ADSC-Exos significantly promoted C2C12 cell proliferation and migration, and enhanced HUVEC angiogenesis. miR-125b-5p mimic treatment increased C2C12 cell proliferation and migration, while an inhibitor reduced these effects. miR-125b-5p was shown to directly bind to the 3' UTR of ACER2, leading to reduced ACER2 mRNA and protein expression. Overexpression of ACER2 counteracted the pro-proliferative and pro-migratory effects of miR-125b-5p.
- In Vivo: ADSC-Exos treatment significantly improved blood perfusion recovery in ischemic hindlimbs of diabetic mice. Histological analysis showed reduced inflammation and collagen deposition, along with increased centronuclear myofibers and neovascularization (both newly formed and mature vessels) in ADSC-Exos treated groups compared to controls.
Limitations and Future Work
The authors acknowledge several limitations and suggest future research directions:
- Other miRNAs in ADSC-Exos: While miR-125b-5p is identified as a key player, the study cannot exclude the possibility that other miRNAs within ADSC-Exos also contribute to the therapeutic effects. Further research is needed to investigate these contributions.
- AMPK Signaling Pathway: The study notes the potential importance of the AMPK signaling pathway in diabetic HLI but did not invest in its depth. Further investigation into its precise role and interaction with miR-125b-5p is warranted.
- ACER2 Function in Diabetic HLI: The study confirmed ACER2 as a target and its role in cell function but lacked in-depth investigation of ACER2's specific function in diabetic HLI.
- ROS and p53 Pathways: Increased ACER2 levels in diabetic HLI may lead to ROS-induced oxidative injury and are related to p53-dependent apoptosis pathways. Further research is needed to explore these connections.
Summary updated